NCT00461786

A Study of Single Agent Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer

A Phase II Evaluation of Pemetrexed (Alimta, LY231514l, IND # 40061) in the Treatment of Recurrent or Persistent Platinum Resistant Ovarian or Primary Peritoneal Carcinoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 51 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: Female
• Age: —
• Healthy volunteers: Not accepted

Summary

The primary purpose of this trial is to estimate the drug effect on tumors in patients with ovarian or primary peritoneal cancers. Patients will receive Pemetrexed every 21 days until disease progression or unacceptable toxicity. This medication will be given over 10 minutes and may be administered intravenously (IV), through a vein in your arm. Vitamin supplementation is a required part of this study.

Conditions

• Ovarian Cancer
• Peritoneal Cancer

Interventions

Type	Name	Description
DRUG	pemetrexed	900 mg/m2, intravenous (IV), every 21 days, until disease progression

Timeline

• Start date: 2004-09-01
• Primary completion: 2007-10-01
• Completion: 2008-05-01
• First posted: 2007-04-18
• Last updated: 2009-12-04
• Results posted: 2009-08-24

Locations

1 site across 1 country: United States